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ABSTRACT

Background: Optimal treatment remains uncertain for patients with cognitive impairment that
persists or returns after standard IV antibiotic therapy for Lyme disease.

Methods: Patients had well-documented Lyme disease, with at least 3 weeks of prior IV antibiotics, current positive IgG Western blot, and objective memory impairment. Healthy individuals
served as controls for practice effects. Patients were randomly assigned to 10 weeks of doublemasked treatment with IV ceftriaxone or IV placebo and then no antibiotic therapy. The primary
outcome was neurocognitive performance at week 12—specifically, memory. Durability of benefit was evaluated at week 24. Group differences were estimated according to longitudinal mixedeffects models.

Results: After screening 3368 patients and 305 volunteers, 37 patients and 20 healthy individuals enrolled. Enrolled patients had mild to moderate cognitive impairment and marked levels of
fatigue, pain, and impaired physical functioning. Across six cognitive domains, a significant
treatment-by-time interaction favored the antibiotic-treated group at week 12. The improvement
was generalized (not specific to domain) and moderate in magnitude, but it was not sustained to
week 24. On secondary outcome, patients with more severe fatigue, pain, and impaired physical
functioning who received antibiotics were improved at week 12, and this was sustained to week
24 for pain and physical functioning. Adverse events from either the study medication or the PICC
line were noted among 6 of 23 (26.1%) patients given IV ceftriaxone and among 1 of 14 (7.1%)
patients given IV placebo; these resolved without permanent injury.

Conclusion: IV ceftriaxone therapy results in short-term cognitive improvement for patients with
posttreatment Lyme encephalopathy, but relapse in cognition occurs after the antibiotic is discontinued. Treatment strategies that result in sustained cognitive improvement are
needed. Neurology® 2008;70:992–1003
GLOSSARY
CDC ⫽ Centers for Disease Control and Prevention; LMM ⫽ longitudinal mixed-effects models; NAART-R ⫽ North American
Adult Reading Test-Revised; PCS ⫽ Physical Component Scale; ITT ⫽ intent-to-treat; VAS ⫽ visual analog scale; WMS-III ⫽
Wechsler Memory Scale.

Supplemental data at
www.neurology.org
Editorial, page 986

Lyme disease, a tick-borne bacterial illness caused by Borrelia burgdorferi, can induce
cognitive deficits when it affects the CNS.1 These deficits, often mild to moderate in
severity, extend across multiple domains of cognitive function, including memory, working memory, verbal fluency, and psychomotor performance.2,3 Although treatment with 4
weeks of IV ceftriaxone usually results in marked improvement, in a subgroup this treatment results in only partial or nonsustained benefit.4,5 Posttreatment cognitive deficits
may reflect residual effects of past infection, continuing effects of current low-grade
B burgdorferi infection, the presence of an unrecognized coinfection, or incorrect diagnoe-Pub ahead of print on October 10, 2007, at www.neurology.org.
From the Department of Psychiatry (B.A.F., J.G.K., K.M.C., E.P., I.S., J.C., H.A.S.), Department of Biostatistics (E.P.), Department of
Neurology (C.B.B.), Department of Medicine (E.D., J.D.), and New York State Psychiatric Institute (B.A.F., J.G.K., K.M.C., E.P., I.S., J.C.,
H.A.S.), Columbia University, New York; and Department of Cell and Molecular Biology, University of Rhode Island, Kingston (D.R.N.).
Primary location of research: Columbia University Medical Center, New York.
This study was funded by a grant from NINDS to Dr. Fallon (R01- NS38636).
Disclosure: Roche Pharmaceuticals supplied ceftriaxone free of charge for this study but were not involved in any other aspect of the study.
Dr. Fallon has given expert testimony at hearings related to Lyme disease and its treatment. The other authors report no conflicts of interest.
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sis. Consequently, clinicians are uncertain
about optimal treatment strategies. For patients in whom no other cause of symptoms
can be found, community practice varies
widely, ranging from no treatment to palliative treatment to use of repeated or longterm antibiotic courses.
To evaluate the benefit of additional IV
antibiotic therapy, we conducted a trial comparing clinical improvement from 10 weeks
of IV ceftriaxone vs IV placebo in patients
with previously treated Lyme disease who
had objective memory impairment and a currently positive IgG Western blot.
METHODS Study participants. Between January 2000
and April 2004, healthy volunteers (controls) and individuals
with a history of Lyme disease (patients) between the ages of 18
and 65 years were recruited; follow-up evaluations were completed by April 2005. The institutional review boards at Columbia University and the New York State Psychiatric Institute
approved the study, and all participants provided written informed consent. Evaluations were conducted at the New York
State Psychiatric Institute and Columbia University Medical
Center. Treatments were conducted at each patient’s home. Patients met the following criteria: (1) history of physiciandocumented erythema migrans or U.S. Centers for Disease
Control and Prevention (CDC)-defined manifestation of Lyme
disease, and a positive or equivocal ELISA confirmed by positive Western blot serology6,7; (2) current positive IgG Western
blot using CDC surveillance criteria, assessed using a single reference laboratory (University Hospital of Stony Brook); (3)
treatment for Lyme disease with at least 3 weeks of IV ceftriaxone, completed at least 4 months before study entry; (4) subjective memory impairment that, by participant report, started
after the onset of Lyme disease; and (5) objective evidence of
memory impairment as documented by the Wechsler Memory
Scale–III8 compared with age-, sex-, and education-adjusted
population norms. These study criteria were conservative and
narrow to enhance diagnostic confidence. Prior IV antibiotic
therapy was required to ensure that all patients had received
treatment considered adequate for neurologic Lyme disease by
published guidelines.9,10
The control sample of healthy volunteers had (1) negative history of Lyme disease, fibromyalgia, or chronic fatigue; (2) negative IgM and IgG Western blot for Lyme
disease; and (3) no evidence of memory impairment on neuropsychological testing.
Patients and controls were excluded if their history revealed a prior learning disability or medical condition that
could confound neuropsychological assessment. Patients
with cephalosporin allergy or a history of major psychiatric
disorder before the onset of Lyme disease were also excluded. The control and patient samples were matched on
the mean, variance, and shapes of the distributions of age
and education, and the distribution of gender.

Study design. Treatment. The controlled phase of this
study consisted of 10 weeks of randomized treatment with
either IV ceftriaxone (2 g/d) or IV placebo (0.9% normal

saline), and then 14 weeks off all antibiotics. Ceftriaxone
was chosen because it is the recommended treatment for
neurologic Lyme disease and has excellent penetration of the
blood– brain barrier.9 A 10-week duration was chosen because of reports of persistent or relapsing symptoms after 3
weeks of IV ceftriaxone, and because of case series suggesting that longer courses of antibiotic therapy may be more
effective.4,11 After week 24, treatment assignment was revealed by a research staff member not involved in data collection, and no further constraints were placed on
subsequent care. Participants underwent one follow-up assessment at week 48. This report concerns only the controlled phases of the study, from baseline to week 24.
Randomization. Patients were assigned in a 2:1 ratio to
IV ceftriaxone or IV placebo, using permuted blocks of size
20 based on a computer-based randomization list. A 2:1 randomization schedule was used to encourage enrollment.
Masking. An unmasked off-site pharmacist, who had no
contact with patients, ensured that patients were sent the
assigned treatment; this pharmacist was the only unmasked
individual during the 24 weeks of each patient’s masked
treatment. The neuropsychological technicians were not
privy to information about adverse events. To assess success
of masking, patients were asked to guess treatment assignment at both the week 12 and 24 evaluations.
Compliance with treatment. Compliance and safety
were monitored by home infusion nurses who visited twice
weekly. Patients had weekly telephone contact with a research physician and monthly in-person evaluations with the
patient’s private physician. Study medication was packaged
in pressured infusion devices, numbered from 1 to 70. Both
the visiting nurse and the research physician recorded the
number of completed infusions. Patients who missed a day’s
dose were instructed to continue in consecutive sequence until all 70 doses were infused.
Sample size. The target sample size of 45 Lyme patients (30
randomized to active treatment and 15 randomized to placebo)
provided at least 80% power to detect an effect size of 1.1 with a
two-sided test with ␣ ⫽ 0.05. Power calculations were based on
the results of an uncontrolled pilot study,4 with the outcome
measure of memory assessed with the Buschke Selective Reminding Test total verbal memory score. Although cognitive
improvement was expected in both visual and verbal memory,
as well as in multiple other cognitive domains, verbal memory
was selected for the power analysis, given the lack of pilot data
for other aspects of cognition.

Assessments. Screening. Subjects were screened for memory impairment with the Wechsler Memory Scale (WMSIII),8 which measures immediate, delayed, and working
memory in auditory and visual domains. Demographically
adjusted t scores were computed for all indices, correcting
for the influence of sex, ethnicity, and education level. Memory impairment was defined as a t score of one or more SD
below population norms on at least one of the six primary
WMS-III indices. Premorbid IQ was estimated using the Barona demographic formula12 and the North American Adult
Reading Test–Revised (NAART-R).13
Outcome measures. The primary clinical outcome
measure assessed neurocognitive performance, and the
primary biologic outcomes assessed brain structure and
function. Relative to the placebo and control groups, IV
antibiotic therapy was hypothesized to lead to superior
outcome in the memory domain scores, as well as across
Neurology 70
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cognitive domains. The cognitive assessments sampled six domains: motor function (finger tapping, simple reaction time,
choice reaction time), psychomotor function (Trail Making
A&B; Digit Symbol), attention (Continuous Performance Test,
Stroop task), memory (Buschke Selective Reminding Test [verbal memory]; Benton Visual Retention Test [visual memory]),
working memory (A, Not B Logical Reasoning Test; N-Back
Test), and verbal fluency (Controlled Oral Word Association
Test and Category Fluency Test). Descriptions of these measures may be found elsewhere.14,15 Scores on these tests were z
transformed relative to either published norms or a reference
sample of healthy controls and were adjusted for the effects of
age, gender, and education. Domain scores represent the average of the z scores for the primary tests within each cognitive
domain. To characterize overall performance, the six domain
scores were averaged to produce a cognitive “index” score; this
index was not used in the primary mixed-model analyses. Brain
imaging measures included MRI and PET scans; these imaging
results will be reported elsewhere.
Assessments of physical outcome included the rheumatologist’s exam (trigger points, total number of joints in pain at rest
or on movement) and self-report measures of fatigue (Fatigue
Severity Scale–1116), pain (McGill Pain Questionnaire–Short
Form17), and physical functioning (Short Form–36 Physical
Component Scale [PCS]18,19). Psychopathology was assessed
with respect to depression (Beck Depression Inventory20), anxiety (Zung Anxiety Scale21), mental functioning (SF-36 MCS18,19),
and global symptoms (SCL-90 Global Symptom Index22).
Time of assessment. Major assessments occurred at baseline, week 12, and week 24. The primary end point for efficacy
analyses was week 12. The week 24 assessments evaluated durability of benefit. Controls were assessed at the same time
points to allow correction for the impact of practice effects on
the repeated neurocognitive measures. The secondary outcome
self-report scales were collected at 4-week intervals (baseline
and weeks 4, 8, 12, 16, 20, and 24). The rheumatologist exam
was conducted at baseline, week 12, and week 24. The lumbar
puncture (for patients) and neurology exam (for all participants) were done only at baseline. The neurologic exam assessed five areas: cranial nerves, reflexes, sensory, motor, and
associated motor (cerebellar and basal ganglia) functions. For
the standardized neurology exam, a summary score (0 –5) indicated the number of areas with at least one minor or major
abnormal finding. An objective neurologic abnormality was
considered major if it was associated with either a significant
deficit or impairment in the person’s functioning.
Laboratory assessments. Screening serum was sent for
Lyme IgM and IgG Western blot testing. Enrolled patients had
serum examined by IFA for signs of coinfection with
Anaplasma phagocytophila (human granulocytic erhlichiosis)
and Babesia microti (Babesiosis). Samples of whole blood and
CSF were tested by PCR assay for B burgdorferi DNA, using
the plasmid ospA primer. CSF was sent for cell count, protein,
glucose, total gammaglobulin, Lyme ELISA, and oligoclonal
bands. Serum and CSF were sent for determination of Bbspecific intrathecal Ab production to University Hospital of
Stony Brook using the whole-cell sonicate ELISA (positive cutoff ⱖ 1.1). To determine whether viable B burgdorferi cells
were present, spinal fluid was cultured in BSKII containing
kanamycin (5 g/mL) at 33°C and was checked weekly for up
to 12 weeks.

Statistical analysis. Efficacy analyses were performed using all randomized participants, the intent-to-treat (ITT)
994
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sample. Lyme patient and healthy controls were compared
with respect to demographic and baseline clinical characteristics, using t tests for continuous measures and 2 tests for
categorical measures.
Tests and estimates of differences between groups (IV antibiotic, IV placebo, and healthy controls) with respect to the
multivariate measure of cognition (six domains: motor, psychomotor, working memory, attention, verbal fluency, and
memory) over time (baseline, week 12, and week 24) were based
on longitudinal mixed-effects models (LMM),23 which account
for the correlation between the domains and between the repeated observations over time.24 The LMM included main effects and all interaction terms. Time was modeled as a nominal
factor rather than a continuous variable.
Including all two- and three-way interactions, the model
for the covariance structure was selected based on maximizing Bayesian information criteria.25,26 Keeping the model for
the covariance as selected, stepwise backward elimination
was used to select the “best” model for the mean structure.
Inference regarding the comparison between the groups was
based on the best model. Significant omnibus tests for ITT
differences among the three groups over time (two-sided ␣ ⫽
0.05) were followed by pairwise comparisons; the p values
for these post hoc tests are reported unadjusted.
Secondary outcome measures were analyzed with LMMs,
using a similar strategy. Healthy controls were not included because practice effects were not of concern. For the outcome
number of joints with pain, a Poisson variable, an appropriate
generalized LMM23 was employed, using log link. As initially
planned, the LMMs included the baseline value of the outcome
as a continuous covariate to account for heterogeneity in clinical characteristics and to remedy potential floor effects. The
significance of the interaction terms was judged at a two-sided
␣ ⫽ 0.15, to avoid the erroneous omission of potentially important effects for which the study was not powered; the significance of a main effect for drug vs placebo was still judged at ␣
⫽ 0.05. To illustrate the impact on outcome of different baseline severity scores, an estimate of the mean response based on
the best model for each outcome was computed at weeks 4, 12,
and 24 for drug and placebo for hypothetical subjects with
baseline symptom severity equal to the lowest (first) or highest
(third) quartile of the observed baseline severities. The reporting of outcomes for “low” and “high” baseline severity is for
illustration purposes only: the actual analysis based on LMMs
included all patients and used baseline severity as a continuous
covariate without dichotomizing it into low and high values.
All analyses were performed using SAS software version 925; the
LMMs were fit using PROC MIXED and PROC GLIMMIX.
To explore whether particular patient subgroups had
preferential benefit from active treatment, ANCOVAs tested
for associations between selected demographic, clinical, and
laboratory variables and the primary and secondary outcomes at week 12 and week 24 that had shown a treatment
effect in the LMM analyses. Treatment group, baseline severity of the outcome measure, and (dichotomous or continuous) potential predictor were examined as fully factorial,
between-subject factors.
RESULTS Study population. Healthy controls. Of
305 individuals contacted by telephone, 58 were
invited for on-site screening, and 20 were enrolled. Reasons for exclusion included laboratory
abnormalities, memory deficits on testing, or

Figure

Flow diagram of patient enrollment

drew from the study between weeks 12 and 24.
Laboratory results for enrolled patients. Blood. All

other exclusions. Of the 20 enrolled, two participants had impaired scores on baseline neuropsychological testing and were excluded.
Patients. Of 3368 initial clinic contacts, 1439 were
excluded because of insufficient prior IV treatment,
and 1316 were excluded because the patient had not
met the CDC criteria for Lyme disease (figure).
Among the remaining 613 patients, 512 were excluded because their serum was not IgG Western
blot positive, and 20 were excluded for other reasons. Of the 81 patients invited to Columbia for
neuropsychological screening, 31 did not have sufficient memory impairment, 12 were not able to provide adequate documentation of their clinical
history, and one patient who had been deemed eligible for the study withdrew for private treatment before randomization. Thirty-seven patients were
randomized to interventions, representing 1% of all
patients screened for the study. Of these 37 patients,
five withdrew from the study during the first 12
weeks: three within the first 3 weeks of therapy (two
because of thrombus and one because of hemolytic
anemia; all three on antibiotic), one after 8 weeks
because of a systemic infection (on placebo), and
one after 10 weeks (on placebo) because of intolerable joint pain that required narcotic medications for
relief. Three additional patients had adverse events
that required early termination of study medication
(one at week 6 and two at week 8), but each of these
patients continued in a masked fashion through to
the week 12 and 24 evaluations. No patients with-

samples were IgG WB positive, and 18 of 37 were
IgM WB positive. No patient samples were PCR
positive using the OspA primer assay. None of
the serum samples were IgM positive on either of
the two coinfection tests, whereas low positive
IgG results were noted on 4 of 37 (10.8%) samples
for Anaplasma phagocytophila and on 10 of 37
(27.0%) samples for Babesia microti.
Cerebrospinal fluid. Baseline lumbar puncture,
conducted in 33 of the 37 patients, revealed few abnormalities: mildly elevated WBC (two samples),
mildly elevated protein (four samples), and elevated
gammaglobulin (one sample). Positive results were
noted for 22 on Lyme ELISA, 28 on IgG WB, and
none on IgM WB. For intrathecal Ab production,
samples tested positive for 4 of 31 (12.9%) patients;
each positive intrathecal sample was also seropositive. No patient had a positive CSF PCR. When cultured, one sample was positive for growth and
revealed spirochetes by both phase contrast and
dark-field microscopy. To exclude contamination
as an explanation, the cells’s DNA was extracted
and was used as a template for PCR amplification of
the spoT gene. Examination of the PCR amplicon
by agarose gel electrophoresis revealed an approximately 3-kbp band, whereas a PCR amplicon from
wild-type strains was approximately 2 kbp. Additionally, the B burgdorferi isolated from the CSF
culture was able to grow when transferred into
BSKII containing kanamycin (5 g/mL) plus streptomycin (100 g/mL). These results strongly suggest
that the B burgdorferi strain found in the CSF culture was the result of contamination by a spoT mutant strain (WC07) of B burgdorferi containing a
deletion of part of the spoT gene plus the insertion
of a streptomycin resistance gene; spoT mutant
strains were under investigation in the lab at the
time of the culture.
Demographics and pretreatment clinical characterization of patients and controls. The patients and

healthy controls did not differ in the matching
variables of age, gender, or education (table 1).
The patients’ clinical histories indicated that all
had rheumatologic symptoms, and most had neurologic symptoms associated with cognitive complaints. Nearly half (49%) had had a prior lumbar
puncture; only three of these patients had had elevated B burgdorferi–specific intrathecal Ab production. The total amount of prior antibiotic
therapy for Lyme disease was extensive, with
57% of the patients in each treatment group having had more than 1 month of prior IV antibiotic
Neurology 70
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Table 1

Demographic and clinical characteristics of all participants by study group
Patients
Ceftriaxone group

Placebo group

Total

Controls

Characteristic

(n ⫽ 23)

(n ⫽ 14)

(n ⫽ 37)

(n ⫽ 18)

Age in years, mean (SD)

45.3 (13.7)

44.8 (12.7)

45.1 (13.2)

45.6 (11.3)

Female, n (%)

14.0 (61.0)

8.0 (57.1)

22.0 (59.0)

13.0 (72.2)

Years of education, mean (SD)

14.7 (2.4)

14.8 (2.7)

14.7 (2.5)

15.6 (2.4)

White, n (%)

23.0 (100)

14.0 (100)

37.0 (100)

17.0 (94.4)

14 (60.9)

7 (50.0)

21 (57.0)

7 (33.9)

Employment, n (%)
Working full- or part-time
School full- or part-time

0 (0.0)

2 (14.3)

2 (5.4)

1 (5.5)

On leave from work or disabled

3 (13.0)

4 (28.6)

7 (18.9)

0 (0.0)

Other

6 (26.1)

1 (7.1)

7 (18.9)

10 (55.6)

Lyme disease symptom history, n (%)
Erythema migrans

13 (56.5)

Arthralgias or myalgias

23 (100.0)

14 (100.0)

37 (100.0)

Arthritis

20 (87.0)

11 (78.6)

31 (83.8)

3 (13.0)

6 (42.9)

9 (24.3)

Facial nerve palsy
Meningitis or encephalitis
Polyneuropathy
Cognitive problems

7 (50.0)

20 (54.1)

3 (13.0)

2 (14.3)

5 (13.5)

18 (78.3)

11 (78.6)

29 (78.4)

23 (100.0)

14 (100.0)

37 (100.0)

Months of prior IV antibiotics, mean (SD)

2.5 (2.0)

1.9 (1.3)

2.3 (1.6)

Months of prior oral antibiotics, mean (SD)

7.9 (10.2)

5.9 (7.6)

7.2 (9.2)

No. of joints with pain at rest or motion

5.9 (4.5)

6.4 (7.2)

6.1 (5.6)†

0.6 (0.7)†

No. of fibromyalgia trigger points

1.4 (2.7)

2.3 (3.4)

1.8 (3.0)†

0.0 (0.0)†

No. of tender joints

1.1 (2.4)

1.1 (2.1)

1.1 (2.3)†

0.1 (0.2)†

No. of swollen joints

0.9 (1.6)

0.3 (.83)

0.7 (1.4)†

0.0 (0.0)†

16 (69.6)

11 (78.6)

27 (73)‡

4 (22.2)‡

Motor exam abnormality

8 (34.8)

6 (42.9)

14 (37.8)*

2 (11.1)*

Associated motor exam

7 (30.4)

5 (35.7)

12 (32.4)

3 (16.7)

Cranial nerves

3 (13.0)

4 (28.6)

7 (18.9)

2 (11.1)

Reflex exam

3 (13.0)

4 (28.6)

7 (18.9)

2 (11.1)

Rheumatology exam, mean (SD)

Neurology exam, n (%)
Sensory exam abnormality

* p ⬍ 0.1.
† p ⬍ 0.01.
‡ p ⬍ 0.001.

therapy. Patients reported having been symptomatic with Lyme disease for a mean of 1.7 (SD 3.5)
years before diagnosis, and they reported having
been ill for a total of 9.0 (SD 6.8) years.
Patients and controls on the screening measures. The
groups did not differ in estimated premorbid IQ
according to the Barona method (111.5 [SD 6.2]
for patients vs 113.7 [SD 5.5] for controls), although healthy controls had superior IQ as estimated by the NAART (108.9 [SD 8.1] for patients
vs 115.9 [SD 6.0] for controls, p ⬍ 0.01). There
were pronounced differences between the groups
in WMS-III scores for immediate memory (93.1
996
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[SD 12.4] for patients and 119.7 [SD 11.4] for controls, p ⬍ 0.01) and delayed (general) memory
(94.7 [SD 10.2] for patients and 122.1 [11.5] for
controls, p ⬍ 0.01). The magnitude of these differences in memory substantially exceeded the
difference between the groups in estimated IQ.
Patients and controls on postscreening measures. Participants were entered into the study based on a
predetermined level of impairment (patients) or
lack of impairment (controls), using the WMS-III.
Because Lyme disease typically affects multiple
aspects of cognition,2,27 patients and controls
were expected to differ at baseline on other cogni-

tive domains as well. It was also expected, based
on prior studies of posttreatment Lyme disease,5,28,29 that the two groups might differ on several of the secondary clinical outcome measures.
Patients and controls differed significantly on
all clinical outcome measures, both primary and
secondary. Mean difference of at least one SD
(moderate impairment) occurred in the psychomotor, memory, working memory, and verbal
fluency domains. In the secondary measures, the
impairment was severe in the physical measures
(fatigue, current pain, physical functioning, joint
pain on exam) and was mild in the psychopathology measures (depression, anxiety, general symptom index, mental component scale). Compared
with published samples, reports of pain were similar to those of postsurgery patients,17 fatigue was
similar to that of patients with multiple sclerosis16, and limitations in physical functioning were
comparable with those of patients with congestive heart failure.19 Individual subject scores on
secondary measures ranged from mild to severe,
reflecting our enrollment criteria, which did not
preselect patients based on a level of impairment
in these areas.
Patients, compared with controls, had significantly more trigger points, joints with pain, and
joint swelling on rheumatologic exam (table 1). Patients averaged 1.8 (SD ⫽ 3.00) trigger points, with
only one subject meeting the criteria for fibromyalgia with more than 10 trigger points. Joint pain was
common, elicited on exam in 35 patients, with pain
on motion (34/37) being more common than tenderness (13/37, McNemar 2 ⫽ 17.39, df ⫽ 1, p ⬍
0.01) or swelling (10/37, McNemar 2 ⫽ 22.04,
df ⫽ 1, p ⬍ 0.01). The number of abnormal areas
on neurologic exam was greater in patients (mean
1.8 ⫾ 1.2, median 2) than in controls (0.67 ⫾ 1.1,
median 0; t ⫽ 3.3, df ⫽ 53, p ⬍ 0.01). Major neurologic abnormalities were infrequent in the patients and absent in the controls (3/37 vs 0/18, p ⫽
NS). However, minor abnormalities on neurologic exam were found in 73% of the patients vs
27.8% of the controls (Fisher p ⬍ 0.01); most frequent was a mild sensory abnormality among the
patients.
Completeness of follow-up. Eighty-seven percent
(32/37) of patients and 100% (18/18) of controls
completed the week 12 acute-phase efficacy evaluation and week 24 follow-up durability evaluation,
representing 20 patients in the ceftriaxone group, 12
in the placebo group, and all healthy controls.
Primary outcome: Treatment effects on neuropsychological tests. Arithmetic means and standard

deviations are given in table 2. The inference re-

garding ITT comparisons between the groups
over time is based on the best-fitting LMM that
contained the main effects for group, time, and
domain, and the two-way interactions of group
by time and group by domain (table 3).
The primary omnibus LMM analysis revealed
a group-by-time interaction effect (p ⫽ 0.04), indicating that with respect to cognition, the groups
(drug, placebo, and healthy controls) differed in
change over time (week 0 to week 12; week 12 to
week 24) across all domains. The lack of a threeway interaction among group, domain, and time
indicates that differential improvement over time
between the domains was not demonstrated as
had been hypothesized for memory and that the
joint effect of time and group can be described
without reference to a cognitive domain. Because
the primary omnibus p value was significant, we
then conducted model-based estimation of the effect of time within groups and pairwise comparisons of the effect of time between the groups.
These comparisons demonstrated within-group
cognitive improvement (as measured by the six
cognitive domains) during the acute course of
treatment (from week 0 to week 12) for the patients given ceftriaxone (p ⬍ 0.01) but not for the
patients given placebo (p ⫽ 0.15) or the healthy
controls (p ⫽ 0.51). The cognitive improvement
between baseline and week 12 in the drug-treated
patients was better than in the healthy controls
(p ⬍ 0.01) and better than in the placebo-treated
patients (p ⫽ 0.053).
During the antibiotic-free interval to week 24,
the patients initially on ceftriaxone lost the preferential cognitive gains seen at week 12, whereas
the two control groups (placebo and healthy volunteers) continued to show the same mild cognitive improvement as they had demonstrated in the
acute phase. At week 24, the within-group improvement from baseline continued to be significant for the drug-treated group, but it was also
now seen in the placebo-treated group. At week
24, the between-group treatment effects were no
longer seen. In summary, the inability of the drugtreated group to sustain the distinguishing acutephase improvement in cognition during the
subsequent antibiotic-free interval resulted in a
loss of the differential treatment effect among the
three groups at week 24.
Secondary outcomes. Arithmetic means are pre-

sented in table e-1 on the Neurology® Web site
(www.neurology.org), and the best-fitting models
for each secondary outcome measure are presented in table e-2. Table e-2 also provides modelbased estimates of the means over time for
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Table 2

Neuropsychological test results (raw scores) by domain, treatment group, and time
Baseline

Week 12

Mean (SD)

Mean (SD)

Effect size*

Mean (SD)

Week 24
Effect size*

Drug group

(n ⫽ 23)

(n ⫽ 20)

12/base

(n ⫽ 20)

24/base

Motor

⫺0.23 (1.34)

0.58 (0.88)

0.67

0.33 (1.05)

0.70

Psychomotor

⫺0.21 (0.75)

0.19 (0.89)

0.54

0.12 (0.88)

0.56

Attention

⫺0.12 (0.76)

0.15 (0.80)

0.27

0.18 (0.83)

0.36

Memory total

⫺0.75 (1.07)

⫺0.44 (1.29)

0.50

⫺0.62 (1.30)

0.37

Buschke

⫺1.13 (1.33)

⫺0.79 (1.71)

0.42

⫺0.98 (1.44)

0.31

Benton
Working memory

⫺0.36 (1.21)

⫺0.08 (1.20)

0.25

⫺0.26 (1.43)

0.16

⫺0.92 (1.09)

⫺0.42 (0.94)

0.52

⫺0.54 (0.89)

0.33

Fluency

⫺0.73 (0.94)

⫺0.38 (1.04)

0.55

⫺0.30 (0.98)

1.1

Index

⫺0.49 (0.63)

⫺0.05 (0.74)

0.81

⫺0.14 (0.68)

1.1

Placebo group

(n ⫽ 14)

(n ⫽ 12)

Motor

⫺0.06 (1.19)

0.06 (1.31)

0.13

0.36 (0.64)

0.49

Psychomotor

⫺0.16 (0.61)

0.14 (0.57)

0.58

0.29 (0.71)

0.88

Attention

(n ⫽ 12)

0.04 (1.20)

0.34 (0.70)

0.40

0.37 (0.92)

0.35

Memory total

⫺0.36 (0.95)

⫺0.20 (0.74)

0.06

⫺0.22 (0.61)

0.03

Buschke

⫺0.78 (1.37)

⫺0.72 (1.44)

⫺0.13

⫺0.86 (1.26)

⫺0.18

0.06 (1.09)

0.33 (0.73)

0.22

0.42 (0.62)

0.29

Benton
Working memory

⫺0.32 (0.73)

⫺0.37 (0.75)

⫺0.34

0.04 (0.70)

0.37

Fluency

⫺0.80 (0.38)

⫺0.49 (0.39)

0.53

⫺0.46 (0.44)

0.60

Index

⫺0.28 (0.54)

⫺0.09 (0.50)

0.30

0.06 (0.46)

0.72

Control group

(n ⫽ 18)

(n ⫽ 18)

Motor

0.58 (0.63)

(n ⫽ 18)

0.56 (0.68)

⫺0.08

0.66 (0.68)

0.15

Psychomotor

0.98 (0.75)

0.93 (0.74)

⫺0.11

1.18 (0.89)

0.38

Attention

0.35 (0.85)

0.60 (0.71)

0.43

0.65 (0.66)

0.59

Memory total

0.56 (0.43)

0.62 (0.49)

0.16

0.67 (0.55)

0.23

Buschke

0.38 (0.76)

0.72 (0.74)

0.51

0.72 (0.86)

0.46

0.73 (0.46)

0.52 (0.65)

⫺0.32

0.62 (0.73)

0.17

Working memory

0.34 (0.69)

0.38 (0.64)

0.01

0.43 (0.70)

0.19

Fluency

0.48 (0.66)

0.57 (0.68)

0.18

0.59 (0.86)

0.21

Index

0.55 (0.40)

0.61 (0.36)

0.26

0.70 (0.37)

0.58

Benton

Benton negative scoring has been adjusted.
An effect size of 0.2 reflects small improvement, 0.5 reflects moderate improvement, and 0.8 reflects large improvement.40

subjects’ baseline severity scores corresponding to
the lowest or highest quartile of the distribution
of baseline scores of all 37 patients. These means
are obtained from the respective LMMs (given in
the right-hand side of table e-2) by substituting
the selected baselines in the models. When the
LMM contained an interaction involving group,
post hoc comparisons between groups were performed within baseline severity level.
The majority of the physical self-report measures (fatigue, current pain, physical functioning)
indicate interaction effects at week 12 favoring
drug over placebo as a function of baseline sever998
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ity, with the drug effect increasing with higher
baseline impairment. Improvement continued to
week 24, but only for current pain and physical
functioning. For example, for physical functioning as measured by PCS, table e-2 indicates a twoway interaction (p ⫽ 0.06) for baseline severity
and treatment, such that the beneficial effect of
drug over placebo increased as baseline severity
increased; model-based comparisons reveal the
main effects of drug vs placebo (p ⬍ 0.05) at high
levels of baseline severity. As an illustration of the
LMM results, figure e-1 shows that among hypothetical subjects starting with a higher current

Table 3

Summary of the model for the six domains of neurocognitive performance
Model information

Type 3 tests for fixed effects
Numerator df

G

T
2

G⫻T

D
2

5

4

259

96.6

G⫻D

T⫻D

G⫻T⫻D

10

Denominator df

53.1

96.6

F test

16.25

13.10

9.46

2.59

259
2.09

p Value

⬍0.01

⬍0.01

⬍0.01

0.04

0.03

Model-based contrasts related to group ⫻ time interaction
Week 12/week 0

Est.

SE

df

t Value

p Value

95% CI

Within group
Drug

0.43

0.09

98.0

5.05

⬍0.01

(0.27,0.61)

Placebo

0.16

0.11

98.3

1.43

0.15

(⫺0.06,0.38)

Control

0.06

0.09

95.3

0.66

0.51

(⫺0.12,0.24)

Between groups
Drug vs placebo

0.28

0.14

98.2

1.96

0.05

(⫺0.01,0.56)

Drug vs control

0.38

0.13

96.6

2.98

⬍0.01

(0.12,0.63)

Placebo vs control

0.10

0.15

97.1

0.69

0.49

(⫺0.10,0.30)

Drug

0.35

0.09

98.0

4.08

⬍0.01

(0.18,0.53)

Placebo

0.31

0.11

98.3

2.78

⬍0.01

(0.09,0.53)

Control

0.15

0.09

95.3

1.61

0.11

(⫺0.03,0.33)

Drug vs placebo

0.04

0.14

98.2

0.30

0.76

(⫺0.24,0.33)

Drug vs control

0.21

0.13

96.6

1.62

0.11

(⫺0.05,0.46)

Placebo vs control

0.16

0.15

97.1

1.12

0.27

(⫺0.13,0.45)

Week 24/week 0
Within groups

Between groups

G ⫽ group (drug, placebo, control); T ⫽ time (baseline/week 0, week 12, week 24); D ⫽ domain (motor, psychomotor, attention, memory, working memory, fluency); SE ⫽ standard error; df ⫽ degrees of freedom.
* Indicates exploration of interaction between variables.

pain severity (visual analog scale [VAS] ⫽ 8.1),
there is a greater improvement in pain for the
drug group compared with placebo (p ⬍ 0.05)
that is sustained to week 24, whereas among those
starting with a lower pain severity (VAS ⫽ 2.1),
there is little difference between treatment
groups.
In a post hoc analysis with time as a continuous variable, we examined whether there would
be a treatment effect for the secondary outcome
measures of current pain, fatigue, and physical
functioning during the 24 weeks if baseline severity were not included as a covariate in the LMM
analysis. No significant interactions (group and
week) or main group effects were noted, except
on one outcome measure (physical functioning,
measured by PCS), for which there was a weak
interaction between group and week (p ⬍ 0.15),
such that improvement in physical functioning
was greater across time for the ceftriaxone group

compared with the placebo group, with the magnitude of improvement increasing to week 24.
On the rheumatologist assessment of joint
pain (at rest and with movement), the treatment
effect was not dependent on baseline severity, but
there was a group-by-time interaction. There was
no difference between drug and placebo at week
12 or at week 24 in improvement compared with
baseline, whereas between weeks 12 and 24 the
placebo-treated patients improved more than the
drug group (p ⫽ 0.052). On measures of psychopathology and its effects (depression, anxiety,
global symptoms, mental functioning), there were
no differences between drug and placebo at weeks
12 or 24, although there was a transient treatment
difference on the global psychopathology index at
week 4 when patients with low baseline symptoms who had received the drug had less improvement than did patients with low baseline
symptoms who had received the placebo.
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Variables associated with outcome measures. Se-

lected baseline variables were examined for interaction effects with treatment group on the
cognitive and self-report physical outcomes. Likelihood of improvement with ceftriaxone vs placebo was not related to demographic variables,
CSF values, or clinical history (amount of prior
oral or IV antibiotic therapy; the interval since
last antibiotic course). Interaction effects between
baseline physical exam and treatment on outcome
were noted. On joint exam, patients with more
joints in pain at baseline had a preferential improvement with ceftriaxone on the measures of
cognitive index at week 12 (p ⫽ 0.06) and at week
24 (p ⫽ 0.04), and on the self-report measures of
fatigue (p ⫽ 0.11) and pain (p ⫽ 0.07) at week 24.
On neurologic exam, patients with more areas of
abnormality at baseline had a preferential improvement with ceftriaxone on the measure of
memory at week 24 (p ⫽ 0.11) and on the selfreport measures of fatigue at week 12 (p ⫽ 0.06)
and week 24 (p ⬍ 0.01) and physical functioning
as measured by PCS (p ⫽ 0.09) at week 24.
Adverse events. Five patients withdrew from the

study because of adverse events: two because of
thrombus (both on drug), one because of staphylococcal infection (on placebo), one because of an
allergic reaction (on drug), and one because of
worsening joint pain (on placebo) that required
narcotic pain medication. Four patients remained
in the study despite adverse events that required
either early termination of study medication
(three on drug; two with allergic reactions, and
one with abdominal pain) or hospitalization (one
on drug; cholecystectomy at week 16); for these
patients, ratings at weeks 12 and 24 continued to
be conducted without revealing treatment randomization. The adverse reactions of seven of
these nine patients were thought likely to have
been directly related to the study treatment (presence of a PICC line or medication), for a rate of
treatment-related adverse events of 6 of 23
(26.1%) among patients given IV ceftriaxone and
1 of 14 (7.1%) among patients given IV placebo;
all patients recovered fully.
Masking. Patients assigned to ceftriaxone did not
differ from those assigned to placebo in their rate
of guessing whether they had received active medication either at week 12 (68.4% vs 53.8%; p ⫽
0.40) or at week 24 (75.0% vs 58.3%, p ⫽ 0.32).
Analyses of covariance found no relationship to
outcome of a patient’s guess of medication vs placebo and the actual treatment assignment at week
12. At week 24, there were trends for patients who
1000
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believed that they had received active medication
to report less fatigue (p ⫽ 0.08) and less impairment in physical function (p ⫽ 0.05), but this
main effect was independent of actual treatment
assignment. Finally, patients who had severe side
effects were not more likely to report a beneficial
effect from ceftriaxone; indeed, there was a trend
for patients with severe side effects to report
worsened physical functioning at week 12.
Compliance. Compliance was excellent. Weekly
notes indicate that patients completed all 70
doses, except for those who terminated early. Of
37 patients who began treatment, 30 completed
the full 10-week course (17 on ceftriaxone; 13 on
placebo). Among the seven who did not complete
the full course, one person on placebo completed
58 doses, and among the six antibiotic noncompleters, the total numbers of completed doses were
5, 11, 19, 35, 54, and 58; patients with the latter
three totals returned for week 12 assessments.

This placebo-controlled, doublemasked trial tested the efficacy and safety of repeated IV antibiotic treatment in a sample of
patients with posttreatment Lyme encephalopathy. Conservative inclusion criteria were used to
attain high diagnostic confidence. More than half
of the patients had prior courses of IV antibiotic
therapy that exceeded the standard recommendations for neurologic Lyme disease. Although enrollment required objective memory deficits, the
patients had generalized, mild to moderate cognitive deficits. They also had more sensory and
joint abnormalities on physical exam and selfreports of marked pain, fatigue, and impaired physical functioning, replicating earlier
findings.4,28
The primary result was that the three groups
(ceftriaxone, placebo, health control) differed in
cognitive improvement over time (p ⫽ 0.04), favoring ceftriaxone at week 12 but not at week 24.
At week 12, the end point for efficacy selected a
priori, patients given 10 weeks of IV ceftriaxone
had better within-group and between-group improvement in cognition compared with the
placebo group or healthy controls. This improvement was manifested broadly across several cognitive domains—not specific to the domain of
memory. Benefits from ceftriaxone exceeded the
benefits expected from retesting, both in the
healthy controls and the placebo group. For the
drug vs placebo comparison, the borderline p
value of 0.053 reflects both the modest magnitude
of cognitive improvement and the small sample
size, and it indicates that this finding has a slightly
DISCUSSION

elevated risk of having occurred by chance: 5.3%
vs 5%. On self-report measures, a benefit of
ceftriaxone relative to placebo was observed at
week 12 for physical functioning, current pain,
and fatigue for those patients with greater severity of symptoms at baseline.
Durability of benefit was assessed at week 24
after patients had been off of all treatment for 14
weeks. At this time point, there was no difference
among the three groups in cognitive improvement
from baseline. Sustained improvement, however,
was noted in physical functioning and current
pain among patients with greater baseline impairment, suggesting that ceftriaxone may have both
short- and long-term benefits for these symptoms.
A post hoc analysis suggested that the ceftriaxone
group’s sustained improvement in physical functioning to week 24 could also be seen when baseline severity of impairment was not included as a
covariate.
Ceftriaxone has both infection-independent
neuroprotective and infection-dependent antimicrobial effects that could account for improvement in both primary and secondary measures.
Ceftriaxone upregulates the expression of glutamate transporters on the astroglia of rat brains
with neuroprotective effects30—presumably because of reduced extracellular glutamate, a potentially neurotoxic neurotransmitter. This could
explain short-duration improvement in that continued exposure to ceftriaxone would be required
for sustained upregulation of the glutamate transporter. Another explanation for the observed relapse is that the course of ceftriaxone may have
killed some borrelia, but it exerted little effect on
other organisms in sequestered sites.31,32 There is
one North American report of persistent B burgdorferi by culture after antibiotic therapy,33 and
there are several such European cases.34-38 However, in our study, the baseline CSF specimens
were PCR- and culture negative for B burgdorferi.
Few variables at baseline showed consistent
associations with the primary or secondary outcome measures, perhaps because of inadequate
sample size, which limits the power to detect interaction effects. However, the analysis suggests
that the physical exam may be an important predictor variable of short- and long-term response,
because patients with more painful joints or more
areas of neurologic abnormality at baseline were
more likely to benefit from ceftriaxone than placebo on various outcome measures.
We did not find evidence that unmasking contributed significantly to the positive results in this
study, because patients in each treatment group

did not differ in the rate of guessing assignment to
ceftriaxone. Further, patients’ guesses had no relation with treatment response at the primary
outcome time point of week 12. At week 24, although patients’ guesses of ceftriaxone were associated with greater improvement in physical
functioning, this was true for both the drug and
placebo groups; when only those who guessed
ceftriaxone were included in the analysis, a nonsignificant pattern continued to be evident of
greater improvement in the drug group compared
with the placebo group, supporting a drug effect
independent of guess. Third, the presence of severe side effects was not associated with a more
favorable outcome on the primary or secondary
measures at either week 12 or 24.
How do these findings compare with those of
other placebo-controlled studies of posttreatment
Lyme disease? In two trials,28 3 months of antibiotics conferred no greater benefit than did placebo on the primary SF-36 functional measure or
the secondary outcome measure of cognition. Inability to detect a treatment effect may reflect a
true failure of repeated antibiotic therapy or limitations of the study design (e.g., lack of severity
standard for study enrollment).28,39 In contrast, in
a study of posttreatment Lyme disease for patients with at least moderate fatigue, improvement at 6 months on the Fatigue Severity Scale
was noted among 64% of patients who received 1
month of IV ceftriaxone vs 18.5% who received
IV placebo (p ⬍ 0.001).29 Improvements in cognition or spinal fluid levels of OspA protein were
not detected, but patients were not required to
manifest impairment on either of these measures
at study entry.29 For post hoc comparison, we reanalyzed our data using the post-Lyme fatigue’s
study enrollment criteria, and we applied the
same definition for response (change ⱖ 0.7 on
FSS). Our results were compatible: at 6 months,
66.7% of ceftriaxone-treated patients vs 25% of
placebo-treated patients were responders (Fisher
exact test, p ⫽ 0.05).
The strengths of this study were recruitment of
a rigorously diagnosed patient sample, use of
quantitative measures of cognition with multiple
alternative forms, use of self-report instruments
employed in other trials to facilitate comparison,
inclusion of a healthy control group to account
for practice effects, and the randomized, placebocontrolled design that included a discontinuation
phase to test durability. Noteworthy is that the
pattern of change and degree of cognitive improvement during the 24 weeks were nearly identical for the healthy volunteers and placeboNeurology 70
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treated patients; the healthy control group,
therefore, served to increase the precision of the
estimates of the treatment effect and to provide
enhanced power for the overall analysis to detect
treatment effects in the active drug group, thus
reducing the risk of a type II error. The primary
limitations of this study were its restrictive inclusion criteria (only 1% of screened patients were
enrolled), the relatively small sample size, and the
lack of posttreatment lumbar puncture or neurologic exam. Therefore, generalizability is uncertain to posttreatment Lyme patients without
cognitive impairment or to seronegative patients
with persistent symptoms.
Conclusions from this study are mixed. At the
primary efficacy end point of week 12, IV ceftriaxone treatment resulted in greater improvement
in cognition and, among the more impaired, in
physical functioning, pain, and fatigue. Clinical
significance, however, depends on long-term effects. Notable were the long-term benefits for the
ceftriaxone group on physical functioning and
pain among the more severely affected patients at
baseline, because these are among the most troubling aspects of posttreatment Lyme disease.28
However, our primary interest in this study was
on cognition, for which the improvement was not
sustained to week 24. Further, adverse effects attributed to IV ceftriaxone occurred in 26% of patients. Therefore, considering both the limited
duration of cognitive improvement and the risks,
10 weeks of IV ceftriaxone and then 14 weeks of
no antibiotic is not an effective strategy for sustained cognitive improvement. Although certain
subgroups (patients with more joint or neurologic
abnormalities) may experience long-term benefit
from ceftriaxone, the predictor analyses were exploratory rather than hypothesis driven, and they
require independent confirmation. Pending such
confirmation, treatment strategies that are safer
and more durable are needed.
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